ISSN 2149-2263 | E-ISSN 2149-2271
The Anatolian Journal of Cardiology - Anatol J Cardiol: 21 (1)
Volume: 21  Issue: 1 - January 2019
1.New Year
Çetin Erol
PMID: 30587717  doi: 10.14744/AnatolJCardiol.2019.1  Page 1
Abstract |Full Text PDF

2.Circular RNA expression profiles of persistent atrial fibrillation in patients with rheumatic heart disease
Miaoyang Hu, Xufeng Wei, Meng Li, Ling Tao, Liping Wei, Minxia Zhang, Hexiang Cheng, Yuan Yuan
PMID: 30587718  doi: 10.14744/AnatolJCardiol.2018.35902  Pages 2 - 10
Objective: To investigate the expression profile of circular RNAs (circRNAs) and proposed circRNA–microRNA (miRNA) regulatory network in atrial fibrillation (AF).
Methods: Atrial tissues from patients with persistent AF with rheumatic heart disease and non-AF myocardium with normal hearts were collected for circRNA differential expression analyses by high-throughput sequencing. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to predict the potential functions of the differentially expressed genes and AF-related pathways. Co-expression networks of circRNA–miRNA were constructed based on the correlation analyses between the differentially expressed RNAs. Quantitative reverse transcription polymerase chain reaction (PCR) was performed to validate the results.
Results: A total of 108 circRNAs were found to be differentially expressed in AF. Among them, 51 were up-regulated, and 57 were down-regulated. Dysregulated circRNAs were validated by quantitative real-time PCR. The GO and KEGG pathway enrichment analyses were executed to determine the principal functions of the significantly deregulated genes. Furthermore, we constructed correlated expression networks between circRNAs and miRNAs. circRNA19591, circRNA19596, and circRNA16175 interacted with 36, 28, and 18 miRNAs, respectively; miR-29b-1-5p and miR-29b-2-5p were related to 12 down-regulated circRNAs, respectively.
Conclusion: Our findings provide a novel perspective on circRNAs involved in AF due to rheumatic heart disease and establish the foundation for future research of the potential roles of circRNAs in AF.

3.Retrospective analysis of 11 cases of primary cardiac valve tumors
Tianbo Li, Chencheng Liu, Yang Luo, Siming Gong, Yingbin Xiao, Xuefeng Wang, Yong Wang
PMID: 30587716  doi: 10.14744/AnatolJCardiol.2018.40325  Pages 11 - 17
Objective: To explore the clinical features and surgical treatment experience of primary cardiac valve tumor.
Methods: The present study retrospectively analyzed the clinical data of 11 patients with primary valvular tumors who underwent surgical treatment in our department from 1980 to 2016. Echocardiography of preoperative patients was indicated as a heart valve tumor. All patients underwent cardiopulmonary bypass surgery after endocardial angiography and positron emission tomography–computed tomography diagnosis, including four tumor resections–valvuloplasty and seven tumor resections–heart valve replacement. Pathological analysis was performed on all tumors. Postoperative cardiac ultrasound was followed up. Pathological analysis was performed on all tumors. All patients underwent postoperative ultrasound follow-up examination.
Results: Primary valvular tumors are rare, accounting for only 0.034% (11/32.728) of extracorporeal circulation surgery in our center. It accounts for 2.8% (11/399) of primary cardiac tumors in the same period. Pathological study indicated that there were 10 cases of benign tumor and 1 case of low-grade sarcoma. After 0.6–16 years of follow-up, the operation effect was satisfactory.
Conclusion: Most of these tumors are papillary fibroelastoma located on the mitral valve, and surgical operation is the best strategy for cardiac primary valve tumors.

4.Whole-exome sequencing reveals a novel mutation of MT-ND5 gene in a mitochondrial cardiomyopathy pedigree: Patients who show biventricular hypertrophy, hyperlactacidemia, pulmonary hypertension, and decreased exercise tolerance
Nianwei Zhou, Lu Tang, Yingying Jiang, Shengmei Qin, Jie Cui, Yanan Wang, Wenqing Zhu, Weipeng Zhao, Cuizhen Pan, Xianhong Shu
PMID: 30587702  doi: 10.14744/AnatolJCardiol.2018.53258  Pages 18 - 24
Objective: The aim of the present study was to determine whether pathogenic mutations were present in families with mitochondrial cardiomyopathy that presented during adolescence.
Methods: The proband was a 21-year-old man who presented clinically with palpitations, chest tightness, pulmonary hypertension, and limited exercise tolerance. Cardiac magnetic resonance imaging studies showed biventricular cardiac hypertrophy. We determine whether pathogenic mutations were present by whole-exome sequencing (WES) in families.
Results: Screening of the family using tandem mass spectrometry showed elevated lactic acid levels, glutaric aciduria, a mildly increased glutarylcarnitine-to-octanoylcarnitine ratio, and normal blood α-glucosidase, which was consistent with a respiratory chain complex 1 metabolic disorder. We identified a novel mutation of MT-ND5, c.1315A>G (p.Thr439Ala). Skeletal muscle biopsy histology showed predominantly ragged red fibers and few ragged blue fibers, which was consistent with mitochondrial myopathy.
Conclusion: In the present study, we identified a novel mutation of MT-ND5, c.1315A>G (p.Thr439Ala), in a family pedigree using WES.

5.The real-life data of hospitalized patients with heart failure: On behalf of the Journey HF-TR study investigators
Ümit Yaşar Sinan, Ahmet Ekmekçi, Benay Özbay, Filiz Akyıldız Akçay, Lütfü Bekar, Yavuzer Koza, Ismail Bolat, Umut Kocabaş, Mehdi Zoghi
PMID: 30587703  doi: 10.14744/AnatolJCardiol.2018.50880  Pages 25 - 30
Objective: Acute heart failure (AHF) is a life-threatening clinical syndrome characterized by rapid onset of heart failure (HF) symptoms and signs and requires urgent therapy. The aim of the present study was to evaluate the overall clinical characteristics, management, and in-hospital outcomes of hospitalized patients with AHF in a large sample of Turkish population.
Methods: The Journey HF-TR study is a cross-sectional, multicenter, non-invasive and observational trial. Patients who were hospitalized with a diagnosis of AHF in the intensive care unit (ICU)/coronary care unit and cardiology wards between September 2015 and September 2016 were included in our study.
Results: A total of 1606 (male: 57.2%, mean age: 67.8±13 years) patients who were diagnosed with AHF were enrolled in the study. Seventeen percent of the patients were admitted to the hospital with a diagnosis of new onset AHF. Hypertension (67%) and coronary artery disease (CAD) (59.6%) were the most frequent underlying diseases. Acute coronary syndrome accompanying HF (14.7%), infection (29.3%), arrhythmia (25.1%), renal dysfunction (23%), and non-compliance with medication (23.8%) were the precipitating factors. The median length of stay in the ICU was 3 days (interquartile range, IQR 1–72) and 7 days (IQR 1–72) for in-hospital journey. The guideline recommended medications were less likely used in our patient population (<73%) before admission and were similar to European and US registers at discharge. The in-hospital mortality rate was 7.6%. Hypertension and CAD were the most frequent underlying diseases in our population similar to other European surveys. Although our study population was younger than other registers, in-hospital mortality was high.
Conclusion: Analyses of such real-world data will help to prepare a national database and distinctive diagnosis and treatment algorithms and to provide observing compliance with the current European Society of Cardiology guidelines for more effective management of HF.

6.The association between the chromosome 9p21 CDKN2B-AS1 gene variants and the lipid metabolism: A pre-diagnostic biomarker for coronary artery disease
Şehime Gülsün Temel, Mahmut Çerkez Ergören
PMID: 30587704  doi: 10.14744/AnatolJCardiol.2018.90907  Pages 31 - 38
Objective: Recent genome-wide association studies have established that polymorphisms within CDKN2B-AS1 of chr9p21.3 locus increased susceptibility to coronary artery disease (CAD) or myocardial infarction. Common variants of CDKN2B-AS1 (including rs4977574 A>G and rs1333040 C>T) are determined to be directly associated with CADs in many populations worldwide and suggested biomarkers for the early detection of CAD. There is a lack of investigation for the association between CDKN2B-AS1 rs4977574 A>G and rs1333040 C>T genetic modifiers and CAD in a Turkish Cypriot population. The aim of the present study was to investigate the potential effects of these variants on susceptibility to developing CAD in a Turkish Cypriot population and their contribution to lipid metabolism.
Methods: Seventy-one patients with angiography-confirmed CAD were recruited to the CAD group, whereas 153 voluntary subjects without CAD symptoms were enrolled to the control group. Genotyping for the CDKN2B-AS1 gene polymorphisms was performed by polymerase chain reaction, followed by restriction fragment length polymorphism analysis.
Results: There is no statistical significant association observed between rs4977574 and rs1333040 single-nucleotide polymorphisms and two studied groups [odds ratio (OR): 0.763, p=0.185, 95% confidence interval (CI): 0.511–1.139 and OR: 1.060, p=0.802, 95% CI: 0.672–1.671, respectively]. However, rs2977574 G and rs1333040 T alleles–the risk alleles–were found to be associated with higher level of serum total cholesterol and lower level of high-density lipoprotein-cholesterol in the CAD group (p=0.019, p=0.006 and p=0.022, p=0.031, respectively). To our knowledge, this is the first study that establishes the effect of rs1333040 on lipid metabolism.
Conclusion: The presence of rs4977574 G and rs1333040 T alleles and interaction may exist as environmental factors associated with lipid metabolism and might be responsible for the development of CAD in a Turkish Cypriot population.

7.Monoamine oxidase A inhibition protects the myocardium after experimental acute volume overload
Christa Huuskonen, Mari Hämäläinen, Timo Paavonen, Eeva Moilanen, Ari Mennander
PMID: 30587705  doi: 10.14744/AnatolJCardiol.2018.37336  Pages 39 - 45
Objective: The molecular pathway leading to myocardial cellular destruction after acute volume overload (AVO) may include monoamine oxidases. The aim of the present study was to investigate whether moclobemide (Mo), a monoamine oxidase inhibitor, protects the myocardium after AVO.
Methods: Sixty syngeneic Fischer rats underwent surgical abdominal aortocaval fistula to induce AVO. Eighteen rats were treated with Mo 10 mg/kg/day and were compared with 42 untreated rats with AVO without treatment. Myocardial recovery was analyzed using quantitative reverse transcription polymerase chain reaction for hypoxia-inducible factor 1-alpha, inducible nitric oxide synthase, interleukin 6, E-selectin, atrial natriuretic peptide (ANP), brain natriuretic peptide, vascular endothelial growth factor-alpha, matrix metalloproteinase 9, chitinase 3-like protein (YKL-40), and transforming growth factor-beta.
Results: After 3 days, the relative number of ischemic intramyocardial arteries in the left ventricle was lower in AVO treated with Mo than in without [0.04 (0.02–0.07) vs. 0.09 (0.07–0.14), point score unit]. After 1 day, ANP was lower in AVO treated with Mo than in without [0.95 (0.37–1.84) vs. 2.40 (1.33–3.09), fold changes from the baseline (FC), p=0.044], whereas after 1 and 3 days, YKL-40 was higher in AVO treated with Mo than in without [22.66 (14.05–28.83) vs. 10.06 (6.23–15.02), FC, p=0.006 and 6.03 (4.72–7.18) vs. 3.70 (2.62–5.35), FC, p=0.025].
Conclusion: Mo decreases intramyocardial arterial ischemia of the left ventricle after AVO while increases YKL-40, reflecting cellular protection during early cardiac remodeling. In the future, adding Mo may be a simple means for myocardial protection after AVO.

8.A rare complication of balloon pulmonary angioplasty: Aortopulmonary window and its treatment
Birgül Varan, Kahraman Yakut, Kürşad Tokel, Süleyman Özkan, Sait Aşlamacı
PMID: 30587706  doi: 10.14744/AnatolJCardiol.2018.24704  Pages 46 - 47
Abstract |Full Text PDF | Video

9.The role of rivaroxaban in left ventricular thrombi
Mahmoud Abdelnaby, Abdallah Almaghraby, Ola Abdelkarim, Yehia Saleh, Basma Hammad, Haitham Badran
PMID: 30587707  doi: 10.14744/AnatolJCardiol.2018.48313  Pages 47 - 50
Abstract |Full Text PDF

10.Confounding factors about microvolt T-wave alternans testing and lifethreatening ventricular arrhytmias
Onur Taşar, Hacer Ceren Tokgöz
PMID: 30587708  doi: 10.14744/AnatolJCardiol.2018.92160  Pages 51 - 52
Abstract |Full Text PDF

11.Author`s Reply
Sinem Özyılmaz, Hamdi Püşüroğlu
PMID: 30587709  Pages 52 - 53
Abstract |Full Text PDF

12.Non-ergot dopamine agonists and heart failure
Yusuf Ziya Şener, Metin Okşul, Cem Çöteli
PMID: 30587710  doi: 10.14744/AnatolJCardiol.2018.76299  Page 53
Abstract |Full Text PDF

13.Author`s Reply
Hilal Erken Pamukcu, Demet Menekşe Gerede Uludağ, Bahar Tekin Tak, Mine Hayriye Sorgun, Tolga Han Efe, Aynur Acıbuca, Cenk Akbostancı, Sibel Turhan
PMID: 30587711  Page 54
Abstract |Full Text PDF

14.An overlooked aspect in the assessment of systolic pulmonary arterial pressure in female patients with hyperthyroidism
Vedat Hekimsoy
PMID: 30587712  doi: 10.14744/AnatolJCardiol.2018.68302  Pages 54 - 55
Abstract |Full Text PDF

15.Author`s Reply
Cristina Tudoran, Mariana Tudoran, Mihaela Vlad, Melania Balas, Gheorghe Nicusor Pop, Florina Parv
PMID: 30587713  Pages 55 - 56
Abstract |Full Text PDF

16.Type I Brugada pattern associated with diabetic ketoacidosis in a patient with type II diabetes mellitus
Semih Kalkan, Ahmet Güner, Macit Kalçık, Çetin Geçmen, Mehmet Özkan
PMID: 30587714  doi: 10.14744/AnatolJCardiol.2018.43789  Page E1
Abstract |Full Text PDF

17.Second and larger than normal aortic annulus triple aortic annulus in a patient with ascending aortic aneurysm and bicuspid aorta
Fatih Kahraman, Engin Akgül, Taha Gürbüzer, Ali Ihsan Parlar
PMID: 30587715  doi: 10.14744/AnatolJCardiol.2018.37074  Pages E2 - E3
Abstract |Full Text PDF | Video

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 The Anatolian Journal of Cardiology

Kare Publishing is a subsidiary of Kare Media.